 |
|
|
|
prIME Oncology invites you to view exciting news released from the 2010 Oncology Annual Meeting
in Chicago.
|
|
|
 |
|
13 JUNE 2010
|
| |
|
This expert interview with Evangelos Terpos, MD, PhD, from the University of Athens School of Medicine, Athens, Greece, and Gareth Morgan, MD, PhD, from Royal Marsden Hospital in Surrey, United Kingdom, along with a special eNewsflash and downloadable slides, discusses the topic of the anticancer effects of bisphosphonates in multiple myeloma focusing on the following data release:
#8021: Evaluating the effects of zoledronic acid (ZOL) on overall survival (OS) in patients (Pts) with multiple myeloma (MM): Results of the Medical Research Council (MRC) Myeloma IX study
|
| |
|
|
| |
|
View the expert interview and opinion with Evangelos Terpos, MD, PhD, and Gareth Morgan, MD, PhD,
and access the downloadable slides 
View eNewsflash
|
 |
|
9 JUNE 2010
|
| |
|
This expert interview with David Spigel, MD, from the Sarah Cannon Research Institute, Nashville, Tennessee, United States, and George Blumenschein, Jr, MD, from the M. D. Anderson Cancer Center, Houston, Texas, United States, along with a special eNewsflash and downloadable slides, discusses the topic of tailoring therapy for patients with advanced non-small cell lung cancer focusing on the following data releases:
#7609: Sorafenib treatment efficacy and KRAS biomarker status in the Biomarker-Integrated Approaches of Targeted Therapy for Lung Cancer Elimination (BATTLE) trial
From AACR: #LB-77 – A randomized double-blind placebo-controlled phase II trial of sorafenib and erlotinib or erlotinib alone in previously treated advanced NSCLC
|
| |
|
|
| |
|
View the expert interview and opinion with David Spigel, MD, and George Blumenschein, Jr, MD
and access the downloadable slides
View eNewsflash
|
|
|
8 JUNE 2010
|
| |
|
#6501: Comparison of nilotinib and imatinib in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): ENESTnd beyond one year
The first interview is an expert review of the data with Andreas Hochhaus, MD, from the Universitätsklinikim Jena in Jena, Germany, and Lee Lokey, MD, from prIME Oncology in Atlanta, Georgia, United States
View the Expert Review of the data with Andreas Hochhaus, MD, and Lee Lokey, MD, and access the
downloadable slides
The second interview is an expert analysis and discussion of clinical implications with Richard Larson, MD, from the University of Chicago Medical Center in Chicago, Illinois, United States, and Lee Lokey, MD, from prIME Oncology in Atlanta, Georgia, United States.
View the Expert Analysis with Richard Larson, MD, and Lee Lokey, MD, and access the
downloadable slides
View eNewsflash
|
 |
|
8 JUNE 2010
|
| |
|
This expert interview with Michael Gnant, MD, from the Medical University of Vienna in Vienna, Austria, and Sunil Verma, MD, MSEd, FRCPC, from the Toronto-Sunnybrook Odette Cancer Centre, Toronto, Ontario, Canada, along with a special eNewsflash and downloadable slides, discusses the topic of the anticancer effects of bisphosphonates in breast cancer focusing on the following data releases:
#10602: Effect of zoledronic acid acts on the interaction between mesenchymal stem cells and breast cancer cells within the bone microenvironment
#512: Impact of body mass index (BMI) on endocrine therapy in premenopausal breast cancer patients: An analysis of the ABCSG-12 trial
#533: Mature results from ABCSG-12: Adjuvant ovarian suppression combined with tamoxifen or anastrozole, alone or in combination with zoledronic acid, in premenopausal women with endocrine-responsive early breast cancer
#1002: Effect of adjuvant zoledronic acid (ZOL) on disseminated tumor cells (DTC) in the bone marrow (BM) of women with early-stage breast cancer (ESBC): Updated results
|
| |
|
View the expert interview and opinion with Michael Gnant, MD, and Sunil Verma, MD, MSEd, FRCPC
and access the downloadable slides
View eNewsflash
|
|
|
7 JUNE 2010
|
| |
|
This expert interview with Kenneth Anderson, MD, and Paul Richardson, MD, from the Dana-Farber Cancer Institute, Boston, Massachusetts, United States, along with a special eNewsflash and downloadable slides, discusses the topic of HDAC inhibitors in multiple myeloma focusing on the following data release:
#8001: Phase Ib study of oral panobinostat (LBH589) plus intravenous bortezomib in patients (Pts) with relapsed (Rel) or Rel and refractory (Ref) multiple myeloma (MM)
|
| |
|
View an expert interview and opinion with Kenneth Anderson, MD, and Paul Richardson, MD, and access
the downloadable slides
View eNewsflash
|
| |
|
|
| |
|
This expert interview with Michel Attal, MD, from Centre Hospitalier de Purpan, Toulouse, France; Philip McCarthy, Jr, MD, from Roswell Park Cancer Institute, Buffalo, New York, United States; and Kenneth Anderson, MD,
from the Dana-Farber Cancer Institute, Boston, Massachusetts, United
States, discusses the topic of newly released data concerning the role
of IMiDs in maintenance therapy for multiple myeloma. An eNewsflash and downloadable slide deck are also available focusing on the following data releases:
#8017:
Phase III intergroup study of lenalidomide versus placebo maintenance
therapy following single autologous stem cell transplant (ASCT) for
multiple myeloma (MM): CALGB 100104
#8018: Lenalidomide maintenance after transplantation for myeloma
|
| |
|
View
the expert interview and opinion with Michel Attal, MD, Philip
McCarthy, Jr, MD, and Kenneth Anderson, MD, and access
the downloadable
slides
View eNewsflash |
 |
|
7 JUNE 2010
|
| |
|
These Clinical Spotlight interviews, with accompanying eNewsflash and downloadable slides, discuss the topic of targeting angiogenesis in the treatment of ovarian cancer with a focus on the following data release:
#LBA1: Phase III trial of bevacizumab (BEV) in the primary treatment of advanced epithelial ovarian cancer (EOC), primary peritoneal cancer (PPC), or fallopian tube cancer (FTC): A Gynecologic Oncology Group study
The first interview is an expert analysis with Gini Fleming, MD, from the University of Chicago, Illinois in the United States, and Bradley Monk, MD, from the University of California Irvine, Orange, California, United States
The second interview is a supplemental perspective and discussion with Bradley Monk, MD, from the University of California Irvine, Orange, California, United States, and Michael Birrer, MD, PhD, from the Massachusetts General Hospital, Boston, Massachusetts in the United States.
View the Primary Expert Analysis with Gini Fleming, MD, and Bradley Monk, MD, and access downloadable slides
View the Supplemental Perspectives and Discussion with Bradley Monk, MD, and Michael Birrer, MD, PhD, and access downloadable slides
View eNewsflash
|
|
|
|
|
|
|
|
|
|
|
|
|
